Cytune Pharma's Unattributed VC Round

Cytune Pharma raised a round of funding on April 18, 2012.

Cytune Pharma is developing a portfolio of immunotherapeutic agents to treat primarily cancer. Cytune's advanced compound, CYP 0150, is a human interleukin-15 uniquely linked to its effector.…

Articles about Cytune Pharma's Unattributed VC Round: